New data on Crohn’s disease presented at Digestive Disease Week in Chicago.
Posted Jul 01 2009 6:46pm
New studies show that patients with moderate to severe Crohn’s disease can maintain remission through three years of therapy with adalimumab (HUMIRA®). It appears that not only has adalimumab demonstrated its efficacy at the beginning of the treatment but it has also shown to maintain its effectiveness over the long-term – pretty important when considering how to manage a chronic condition like Crohn’s disease.
A secondary analysis of the same study demonstrated that patients being treated with adalimumab for Crohn’s disease may also be able to achieve long-term steroid-free remission.